Get started
Author

Nicolas Veillard

Observed institutions: University of Geneva, Institute of Cancer Research, King's College London, Rothamsted Research, Cancer Research UK, Adc Therapeutics (Switzerland)
ORCID: 0009-0002-7536-2519
Observed ORCID: 0009-0002-7536-2519
OpenAlex ID: A5059307227
Short Double-stranded RNAs with an Overhanging 5′ ppp-Nucleotide, as Found in Arenavirus Genomes, Act as RIG-I Decoys
2010 · Jean-Baptiste Marq, Stéphane Hausmann, et al. · Journal of Biological Chemistry · 79
PDF
Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases
2012 · John J. Caldwell, Nicolas Veillard, et al. · Tetrahedron · 23
PDF
Abstract 736: Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity
2018 · Nicolas Veillard, Paolo Andriollo, et al. · Cancer Research · 6
Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b
2024 · Elizabeth Horsley, Asma Jabeen, et al. · Cancer Research · 4
Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody–Drug Conjugate (ADC) Payloads
2019 · Nicolas Veillard, Francesco Cascio, et al. · Royal Society of Chemistry eBooks · 4
Synthesis of novel pyrrolobenzodiazepine (PBD) C1-substituted monomers and dimers with DNA-binding activity and cytotoxicity
2025 · George Procopiou, Paul J.M. Jackson, et al. · Bioorganic & Medicinal Chemistry Letters · 3
Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
2024 · Nicola Tsang, Nicolas Veillard, et al. · Cancer Research · 3
Abstract 4779: In silico design, synthesis and evaluation of a new family of C1-substituted pyrrolobenzodiazepines (PBDs)
2016 · Paul J. M. Jackson, George Procopiou, et al. · Cancer Research · 2
A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation
2026 · Sofia Srdanovic, Alina Chrzastek, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2026 · Asma Jabeen, Ben Leatherdale, et al. · Molecular Cancer Therapeutics
PDF
Abstract 6334: In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for the treatment of solid tumors
2022 · Paul J. Jackson, Paolo Andriollo, et al. · Cancer Research
Abstract C030: A new low potency DNA guanine monoalkylating ADC payload with enhanced i n vivo tolerability
2019 · Nicolas Veillard, Paolo Andriollo, et al. · Molecular Cancer Therapeutics
Abstract 211: A new class of sequence-selective DNA cross-linking ADC payloads with increased in vivo tolerability
2019 · George Procopiou, Jennifer Auer, et al. · Cancer Research
Abstract 211: A new class of sequence-selective DNA cross-linking ADC payloads with increasedin vivotolerability
2019 · George Procopiou, Jennifer Auer, et al. · Experimental and Molecular Therapeutics
Works count: 14
Citation count: 124
H-index: 4
I10-index: 2
Year
Topic
Type